1. Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica 2017; 102: 150-159
2.
Perwein T, Lackner H, Ebetsberger-Dachs G, Beham-Schmid C, Zach K, Tamesberger M, et al. Management of children and adolescents with gray zone lymphoma: a case series. Pediatr Blood Cancer 2020; 67: e28206.
3.
Younes A, Ansell SM. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol 2016; 53: 186-189.
4.
Rosales YMZ, Mesquita JL, Garcia YDO, Paz FRF, Campos NCB, Leitão JPV, et al. Use of checkpoint inhibitors in gray zone lymphoma. Hematol Oncol Stem Cell Ther 2023; 16: 315-319.
5.
Tomassetti S, Chen R, Dandapani S. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol 2019; 10: 2040620719841591.
6.
Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, et al. PD-1 blockade in mediastinal gray-zone lymphoma. N Engl J Med 2017; 377: 89-91.
7.
Sławiński L, Sołek J, Miłkowska-Dymanowska J, Dorota Jesionek- Kupnicka, Joanna Góra-Tybor, Damian Mikulski, et al. Primary pulmonary Hodgkin’s lymphoma mimicking granulomatosis with polyangiitis – a case report of diagnostic and therapeutic dilemmas. Contemp Oncol 2023; 27: 113-117.
8.
Simon Z, Virga B, Pinczés L, Méhes G, Miltényi Z, Barna S, et al. Transition between diffuse large B-cell lymphoma and classical Hodgkin lymphoma – our histopathological and clinical experience with patients with intermediate lymphoma. Pathol Oncol Res 2021; 27: 625529.
9.
Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, et al. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin’s lymphoma after rituximab therapy. Cancer Sci 2009; 100: 54-61.
10.
Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, et al. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 2017; 179: 503-506.
11.
Kritharis A, Pilichowska M, Evens AM. How I manage patients with grey zone lymphoma. Br J Haematol 2016; 174: 345-50.
12.
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 2015; 90: 778-783.
13.
Fedele R, Martino M, Recchia AG, Irrera G, Gentile M, Morabito F. Clinical options in relapsed or refractory Hodgkin lymphoma: an updated review. J Immunol Res 2015; 2015: 968212
14.
Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, et al. A prospective study of mediastinal gray-zone lymphoma. Blood 2014; 124: 1563-1569.
15.
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkMate 436 study. J Clin Oncol 2019; 37: 3081-3089.
16.
Zinzani PL, Chen R, Armand P. Pembrolizumab monotherapy in patients with primary refractory classical Hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma 2020; 61: 950-954.
17.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065-2071.
18.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021; 22: 512-524.
19.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood 2023; 142: 878-886.
20.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood 2023; 142: 141-145.
